---
document_datetime: 2023-09-21 19:04:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/evotaz-epar-all-authorised-presentations_en.pdf
document_name: evotaz-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7261091
conversion_datetime: 2025-12-25 08:45:34.958785
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Numbers   | Invented name   | Strength        | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size                       |
|-------------------|-----------------|-----------------|-----------------------|---------------------------|-----------------------|---------------------------------|
| EU/1/15/1025/001  | EVOTAZ          | 300 mg / 150 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets                      |
| EU/1/15/1025/002  | EVOTAZ          | 300 mg / 150 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 90 (3 x 30) tablets (multipack) |